ABR-238901 is an oral, active S100A8/A9 blocker that inhibits the interaction of S100A8/A9 with its receptors RAGE(receptor for advanced glycation end products) and TLR4 (toll-like receptor 4). ABR-238901 has potential as a compound for the treatment of myocardial infarction (MI).

98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

H2O:0.1 mg/mL (insoluble),DMSO:30.0 mg/mL (76.0 mM)

ABR-238901, given at a dose of 30 mg/kg/day through gavage over a period of 3 weeks, demonstrates reduced angiogenesis and lowered levels of IL6 and IL10 in MDSCs [1]. When ABR-238901 (30 mg/kg/day via gavage) is combined with Bortezomib (0.6 mg/kg via subcutaneous injection, twice a week), it leads to a decreased tumor burden compared to using either agent alone [1]. In C57BL/6NRJ mice with myocardial ischemia resulting from permanent coronary artery ligation, ABR-238901 administered at a dose of 30 mg/kg via intraperitoneal injection for the initial 3 days, followed by continuous oral administration daily for 21 days, induces progressive deterioration of cardiac function and accelerates left ventricular remodeling. However, when ABR-238901 is administered during the first 3 days post-myocardial infarction, it limits inflammatory damage and promotes a reparative environment [2].